HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alex Shimmings

Alexandra has more than 20 years' experience covering pharmaceutical and biotech R&D. An early interest in medicine, and a dawning realization that being a doctor was not for her, led to a degree in Biochemistry and Microbiology at the University of Leeds, and a move to London to pursue a career in medical journalism. Now Scrip's Managing Editor, Alex has held a variety of roles on the publication since starting as a science reporter in 1998. She instigated some of Scrip's signature features, such as the Pipeline Watch and New Active Substance lists, and also casts an editorial eye over the annual Scrip Awards. Alex's main work interests lie in novel drugs and pharmaceutical and biotech R&D, and she also enjoys medical history and current affairs.

Latest From Alex Shimmings

AZ’s Fasenra Joins GSK’s Nucala In Nasal Polyp Pursuit Of Sanofi’s Dupixent

Further competition to Sanofi/Regeneron’s Dupixent in nasal polyps is on the horizon but the newcomers will have some catching up to do.

Companies Clinical Trials

DAPA-CKD Data Put AstraZeneca’s Farxiga Out Front

A 39% relative risk reduction in the primary endpoint for the DAPA-CKD study and a 31% reduction in all-cause mortality prime Farxiga for a new chronic kidney disease indication following filings due in the next few months.

Clinical Trials Companies

Novartis Novel STAMP Inhibitor Passes First Phase III Test In CML

Phase III data for asciminib suggest it could provide a new avenue of therapy for chronic myeloid leukemia patients who are running out of treatment options.

Clinical Trials Companies

Onconova On The Edge After Phase III Rigosertib MDS Failure

Onconova’s lead product, rigosertib, has failed in a Phase III study in myelodysplastic syndromes, sending its share price tumbling by 66%.

Clinical Trials Cancer

Novartis Hits Spartalizumab Phase III Setback In Melanoma

Novartis’s attempts to enter the PD1 market by combining its investigational immunotherapy spartalizumab with its Tafinlar and Mekinist BRAF/MEK combination have come unstuck, leaving Roche to the field.

Companies Clinical Trials

Anti-Aging Firm Unity Stumbles At First Major Hurdle

Unity is set to drop its lead product based on its senescent cell science as it fails in a Phase II study in osteoarthritis of the knee. Focus switches to ophthalmic product.

Clinical Trials Companies
See All
UsernamePublicRestriction

Register